IP Library › Granted Patent US 12,227,556
Granted Patent B2
US 12,227,556 · App. 17/484,721 · Granted Feb 18, 2025

Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods

Inventors: Gisela Schimmack (Tuebingen, DE); Annika Sonntag (Tuebingen, DE); Heiko Schuster (Tuebingen, DE); Daniel Johannes Kowalewski (Tuebingen, DE); Michael Roemer (Tuebingen, DE); Jens Fritsche (Tuebingen, DE); Oliver Schoor (Tuebingen, DE); Toni Weinschenk (Tuebingen, DE); Harpreet Singh (Tuebingen, DE)
Assignee: Immatics Biotechnologies GmbH
C07K14/70514A61K35/17A61K39/0011A61K39/001186C07K14/70517C07K14/70539C07K16/00C12N5/0636A61K2039/5156A61K2039/5158A61K2039/605C07K7/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,556
App. No.
17/484,721
Granted
Feb 18, 2025
Kind
B2
Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claims (17)

1. An isolated peptide consisting of the amino acid sequence YVYANHFTEA (SEQ ID NO: 291) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

2. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

4. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

5. The composition of claim 4 , wherein the peptide is in the form of a chloride salt.

6. The composition of claim 4 , wherein the peptide is in the form of an acetate salt.

7. The composition of claim 4 , further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

8. The composition of claim 7 , wherein the adjuvant is IL-2.

9. The composition of claim 7 , wherein the adjuvant is IL-7.

10. The composition of claim 7 , wherein the adjuvant is IL-12.

11. The composition of claim 7 , wherein the adjuvant is IL-15.

12. The composition of claim 7 , wherein the adjuvant is IL-21.

13. A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises water and a buffer.

14. The composition of claim 7 , wherein the adjuvant is IL-1.

15. The composition of claim 7 , wherein the adjuvant is IL-4.

16. The composition of claim 7 , wherein the adjuvant is IL-13.

17. The composition of claim 7 , wherein the adjuvant is IL-23.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2021
From: SCHIMMACK, GISELA; SONNTAG, ANNIKA; SCHUSTER, HEIKO; KOWALEWSKI, DANIEL JOHANNES; ROEMER, MICHAEL; FRITSCHE, JENS; SCHOOR, OLIVER; WEINSCHENK, TONI; SINGH, HARPREET
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 057593/0130 →
Priority Claims (1)
DE 10 2018 132 617.3 · Dec 18, 2018 · national
Continuity (4)
Continuation 16717142 · Dec 17, 2019
Provisional Application 62884507 · Aug 8, 2019
Provisional Application 62781342 · Dec 18, 2018
Related Publication 20220008472A1 · Jan 13, 2022
References Cited (42)
US 10092636B2 · Binder · 2018 [cited by applicant]
US 10357551B2 · Weinschenk et al. · 2019 [cited by applicant]
US 10793618B2 · Moergelin et al. · 2020 [cited by applicant]
US 11135246B2 · Walz et al. · 2021 [cited by applicant]
US 11324812B2 · Mahr et al. · 2022 [cited by applicant]
US 11542303B2 · Walz et al. · 2023 [cited by applicant]
US 20110318380A1 · Brix et al. · 2011 [cited by applicant]
US 20150125477A1 · Kuttruff-Coqui et al. · 2015 [cited by applicant]
US 20180207251A1 · Weinschenk et al. · 2018 [cited by applicant]
US 20200188438A1 · Schimmack et al. · 2020 [cited by applicant]
US 20210061914A1 · Jooss et al. · 2021 [cited by applicant]
US 20210161962A1 · Walz et al. · 2021 [cited by applicant]
US 20210322478A1 · Walz et al. · 2021 [cited by applicant]
US 20220313805A1 · Mahr et al. · 2022 [cited by applicant]
EP 1118860A1 · 2001 [cited by applicant]
JP 2018510628A · 2018 [cited by applicant]
JP 2018518937A · 2018 [cited by applicant]
WO 0052163A1 · 2000 [cited by applicant]
WO 02072627A2 · 2002 [cited by applicant]
WO 03008537A2 · 2003 [cited by applicant]
WO 2004022709A2 · 2004 [cited by applicant]
WO 2007053956A1 · 2007 [cited by applicant]
WO 2010037395A2 · 2010 [cited by applicant]
WO 2015014820A1 · 2015 [cited by applicant]
WO 2018138257A1 · 2018 [cited by applicant]
WO 2018158455A1 · 2018 [cited by applicant]
WO 2018189148A1 · 2018 [cited by applicant]
WO 2018189152A1 · 2018 [cited by applicant]
Berge et al. (J. Pharm. Sci. Jan. 1977; 66 (1): 1-19). [cited by examiner]
Paulekuhn et al. (J. Med. Chem. Dec. 27, 2007; 50 (26): 6665-72). [cited by examiner]
Nakagawa et al. (Biophys J. Apr. 1, 2007; 92 (7): 2570-82). [cited by examiner]
He et al. (Life Sci. 1999; 65 (4): 355-68). [cited by examiner]
Ljunggren et al. (Nature. Aug. 2, 1990; 346 (6283): 476-80). [cited by examiner]
Bilich et al. (Blood. Feb. 7, 2019; 133 (6): 550-565). [cited by examiner]
Stevens et al. (Eur. J. Immunol. Apr. 1998; 28 (4): 1272-9). [cited by examiner]
Hervé et al. (Mol. Immunol. Feb. 1997; 34 (2): 157-63). [cited by examiner]
Chapuis et al., “Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients,” Sci Transl Med, (2013), vol. 5, No. 174: 174ra27. [cited by applicant]
German Office Action issued in DE 10 2018 132 617.3, mailed Aug. 2, 2019. [cited by applicant]
Faridi, et al., “A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands,” Science Immunology, vol. 3, Issue 28 (Oct. 26, 2018). [cited by applicant]
Bassani-Sternberg, et al., “Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry,” Nat Commun, 7:13404 (Nov. 21, 2016). [cited by applicant]
Charrier, et al., “Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis,” Electrophoresis, 22(9):1861-6 (May 2001). [cited by applicant]
Hassan, et al., “The human leukocyte antigen-presented ligandome of B lymphocytes,” Mol Cell Proteomics;12(7):1829-43 (Jul. 2013). [cited by applicant]